Show simple item record

dc.contributor.authorSánchez, Ricardo
dc.contributor.authorRibera, Jordi
dc.contributor.authorMorgades, Mireia
dc.contributor.authorAyala, Rosa
dc.contributor.authorOnecha, Esther
dc.contributor.authorRuiz-Heredia, Yanira
dc.contributor.authorJuárez-Rufián, Alexandra
dc.contributor.authorde Nicolás, Rodrigo
dc.contributor.authorSanchez-Pina, Jose
dc.contributor.authorVives, Susana
dc.contributor.authorZamora, Lurdes
dc.contributor.authorMercadal, Santiago
dc.contributor.authorColl, Rosa
dc.contributor.authorCervera, Marta
dc.contributor.authorGarcía, Olga
dc.contributor.authorRibera, Josep-Maria
dc.contributor.authorMartinez-Lopez, Joaquin 
dc.date.accessioned2020-09-03T12:22:32Z
dc.date.available2020-09-03T12:22:32Z
dc.date.issued2020
dc.identifier.citationBlood Cancer J. 2020;10(4):43.es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/10961
dc.description.abstractBCR-ABL1-like B-cell precursor acute lymphoblastic leukemia (BCP-ALL) remains poorly characterized in adults. We sought to establish the frequency and outcome of adolescent and adult BCR-ABL1-like ALL using a novel RNA-Seq signature in a series of patients with BCP-ALL. To this end, we developed and tested an RNA-Seq custom panel of 42 genes related to a BCR-ABL1-like signature in a cohort of 100 patients with BCP-ALL and treated with risk-adapted ALL trials. Mutations related to BCR-ABL1-like ALL were studied in a panel of 33 genes by next-generation sequencing (NGS). Also, CRLF2 overexpression and IKZF1/CDKN2A/B deletions were analyzed. Twenty out of 79 patients (12-84 years) were classified as BCR-ABL1-like (25%) based on heatmap clustering, with significant overexpression of ENAM, IGJ, and CRLF2 (P ≤ 0.001). The BCR-ABL1-like subgroup accounted for 29% of 15-60-year-old patients, with the following molecular characteristics: CRLF2 overexpression (75% of cases), IKZF1 deletions (64%), CDKN2A/B deletions (57%), and JAK2 mutations (57%). Among patients with postinduction negative minimal residual disease, those with the BCR-ABL1-like ALL signature had a higher rate of relapse and lower complete response duration than non-BCR-ABL1-like patients (P = 0.007). Thus, we have identified a new molecular signature of BCR-ABL1-like ALL that correlates with adverse prognosis in adult patients with ALL.es_ES
dc.description.sponsorshipThe authors would like to thank all the participants of the PETHEMA group. This project was funded in part by CRIS CANCER FOUNDATION.es_ES
dc.language.isoenges_ES
dc.publisherNature Publishing Groupes_ES
dc.relation.isversionofPublisher's versiones_ES
dc.rights.urihttp://creativecommons.org/licenses/by-nc-sa/4.0/*
dc.subjectMINIMAL RESIDUAL DISEASEes_ES
dc.subjectHIGH-RISKes_ES
dc.subjectB-ALLes_ES
dc.subjectCLASSIFICATIONes_ES
dc.subjectIKZF1es_ES
dc.subjectKINASEes_ES
dc.titleA novel targeted RNA-Seq panel identifies a subset of adult patients with acute lymphoblastic leukemia with BCR-ABL1-like characteristics.es_ES
dc.typeArtículoes_ES
dc.rights.licenseAtribución-NoComercial-CompartirIgual 4.0 Internacional*
dc.identifier.pubmedID32332702es_ES
dc.format.volume10es_ES
dc.format.number4es_ES
dc.format.page43es_ES
dc.identifier.doi10.1038/s41408-020-0308-3es_ES
dc.contributor.funderCRIS against Cancer foundationes_ES
dc.description.peerreviewedes_ES
dc.identifier.e-issn2044-5385es_ES
dc.relation.publisherversionhttps://doi.org/10.1038/s41408-020-0308-3.es_ES
dc.identifier.journalBlood cancer journales_ES
dc.repisalud.institucionCNIOes_ES
dc.repisalud.orgCNIOCNIO::Unidades técnicas::Unidad de Investigación Clínica de Tumores Hematológicos H12O-CNIOes_ES
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses_ES


Files in this item

Acceso Abierto
Thumbnail
Acceso Abierto
Thumbnail
Acceso Abierto
Acceso Abierto
Acceso Abierto

This item appears in the following Collection(s)

Show simple item record

Atribución-NoComercial-CompartirIgual 4.0 Internacional
This item is licensed under a: Atribución-NoComercial-CompartirIgual 4.0 Internacional